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Summary--The growth of the majority of prostate tumors is androgen-dependent, for which 
the presence of a functional androgen receptor is a prerequisite. Tumor growth can be 
inhibited by blockade of androgen receptor action. However, this inhibition is transient. To 
study the role of the androgen receptor in androgen-dependent andandrogen-independent 
prostate tumor cell growth, androgen receptor mRNA expression was monitored in six 
different human prostate tumor cell lines and tumors, which were grown either in vitro or by 
transplantation (male) nude mice. Androgen receptor mRNA was clearly detectable in
three androgen-dependent (sensitive) tumors and absent or low in three androgen-independent 
tumors. Growth of the LNCaP prostate tumor cell line can be stimulated both by androgens 
and by fetal calf serum. In the former situation androgen receptor mRNA expression is 
downregulated, whereas in the latter no effect on androgen receptor mRNA levels can be 
demonstrated. Sequence analysis howed that the androgen receptor gene from LNCaP ceils 
contains a point mutation in the region encoding the steroid-binding domain, which confers 
an ACT codon encoding a threonine residue to GCT, encoding alanine. 
INTRODUCTION 
The androgen receptor is a member of the 
steroid/thyroid hormone/retinoic a id family of 
ligand-responsive transcription regulators (see 
for recent reviews [1-4]). The primary structure 
of the androgen receptor has been deduced 
from the sequence of the molecular cloned 
cDNA[5-11]. Steroid receptors are able to 
bind to a specific sequence (hormone responsive 
element) in the control region of target genes 
and regulate transcription of these genes. 
All members of the steroid receptor family 
show a similar functional domain compo- 
sition [1-4]. The N-terminal region is variable in 
size and in amino acid composition and is 
involved in modulation of transcription activity. 
The transcription modulating domain is fol- 
lowed by the DNA-binding domain, which is 
highly conserved and which is structurally 
folded in two so-called zinc finger motifs. The 
C-terminal portion of the protein is essential for 
ligand binding and is also important for tran- 
scription activation and receptor dimerization. 
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The regulation of prostate development is a 
complex process, which will involve an interplay 
of many mutually fine-tuned regulatory systems. 
It is well established that the androgen receptor 
and its cognate ligands (testosterone and di- 
hydrotestosterone) play an essential role in this 
process [12]. In the developing prostate the 
androgen receptor seems to be mainly expressed 
in the mesenchymal cells. In later stages of 
development androgen receptor expression can 
also be visualized in the epithelial cells. Recent 
studies with specific poly- and monoclonal anti- 
bodies show that in the mature human prostate 
the androgen receptor is present in the secretory 
epithelial cells and absent in the basal cell layer. 
The level of androgen receptor expression i  the 
stromal cells seems to be variable [9, 13-15]. 
The growth of the majority of prostate 
tumors is androgen-dependent[16]. Although 
initially endocrine intervention is very effective, 
in essentially all cases an androgen-independent 
tumor continues to grow. The molecular basis 
for the eventual failure of endocrine therapy is 
not known. Because of the central role of the 
androgen receptor in normal prostate develop- 
ment and in the growth of androgen-dependent 
tumors we investigated the expression of andro- 
gen receptor mRNA in human prostate tumors 
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grown in vitro and & vivo. In addition, we 
studied the molecular structure of the androgen 
receptor of the LNCaP prostate tumor cell 
line [17]. 
EXPERIMENTAL 
Growth of prostate tumors and prostate tumor 
cell lines 
LNCaP [17] and PC-3 [18] cells were cultured 
in RPMI 1640 supplemented with 5% fetal calf 
serum (FCS) and antibiotics. PC-82, PC-EW, 
PC-133 and PC-135 prostate tumors were 
propagated as transplants on male nude mice 
as described [19-21], frozen in liquid nitrogen 
directly after removal and kept at -70°C until 
further use. 
For examination of regulation of androgen 
receptor mRNA expression, LNCaP cells were 
grown in medium containing steroid-depleted 
(dextran-charcoal treated) serum for a period of 
6 days. Next, either the synthetic androgen 
methyltrienoione (R1881, 10 -~°M; NEN, 
Boston) or FCS (5%) was added. Incubation 
was continued for 6 days, cells were harvested 
and directly used for RNA isolation. A control 
culture was continuously kept in steroid- 
depleted medium during the same time period. 
Northern blot analysis 
Isolation of total cellular RNA from the 
different cell lines and tumors was carried out 
by the guanidinium thiocyanate method[22]. 
Northern blot analysis was performed with gly- 
oxal denatured RNA, separated by electro- 
phoresis on a 1% agarose gel and transferred to
a nylon membrane (Genescreen, NEN, Boston). 
Probes (0.5 kb Eco RI-Eco RI fragment, andro- 
gen receptor cDNA [7] and prostate-specific 
antigen cDNA clone PA 525 [23]) were labeled 
by standard procedures [24]. Hybridization was 
under stringent conditions in the presence of 
50% formamide for 16 h at 42°C. After washing 
twice with 2 x SSC at 20°C, twice with 2 x SSC, 
0.1% SDS for 20 min at 65~'C, and once with 
! x SSC at 20°C, filters were dried and exposed 
to X-ray film at -7 f fC  using intensifying 
screens. 
Sequence analysis of the androgen receptor gene 
and cDNA of LNCaP cells 
Total RNA and genomic DNA were iso- 
lated from LNCaP cells by standard pro- 
cedures [22, 25]. cDNA was prepared using 4/~g 
of total RNA, 100 ng of a primer complemen- 
tary to a fragment of the Y-untranslated region 
of the androgen receptor mRNA and 10 units 
AMV reverse transcriptase (Promega, Madison, 
WI) in a standard protocol (Promega). Exons 
2-7 and the protein coding part of exon 8 of the 
androgen receptor gene [26] were amplified from 
1/~g of genomic DNA by the polymerase chain 
reaction[27] using l~g of DNA and intron- 
specific oligonucleotides as primers. For amplifi- 
cation of cDNA fragments, 2% of the first 
strand cDNA reaction mix and exon-specific 
primers were used. Amplification was per- 
formed in a Bioexcellence DNA incubator 
during 24 cycles. Standard conditions were: 
denaturation for 1 min at 95°C, annealing for 
2 min at 60°C and extension for 1-5 min at 
70°C. For sequencing, amplified fragments were 
made blunt ended, inserted in M l3mpl8 and 
sequenced by the dideoxy chain termination 
method [28]. 
RESULTS 
Androgen receptor mRNA expression i  prostate 
tumors~cell lines 
Six different human prostate tumors/cell lines 
were investigated for the expression of androgen 
receptor mRNA by Northern blot analysis. The 
PC-133 and PC-135 tumors are androgen- 
independent and can be propagated by trans- 
plantation on nude mice [21]. The PC-82 and 
PC-EW tumors can be propagated on male 
nude mice and are androgen-dependent [19-21]. 
PC-3 [18] and LNCaP[17] are cell lines which 
can be grown in vitro; the LNCaP cell line is 
androgen-sensitive, whereas the growth of PC-3 
cells is androgen-independent. Previously it has 
been reported that the PC-82, PC-EW and 
LNCaP cells contain high levels of androgen 
receptor, whereas the androgen receptor is ab- 
sent or present at low concentration (PC-3) in 
the other cell lines/tumors [17, 29, 21 and refs 
herein]. The results of the Northern blot exper- 
iments are summarized in Table 1. The ex- 
pression of the androgen receptor mRNA 
Table I. Androgen receptor mRNA expression in human prostate 
tumor cell lines and transplanted tumors 
Androgen AR 
dependent AR protein 
(sensitive) mRNA (refs [17, 21,29]) 
PC-3 - - + ' - 
PC-82 + + + + + 
PC-EW + + + + + 
PC.133 . . . . .  
PC-135 
LNCaP + + + + + + + 
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correlates precisely with androgen receptor 
protein levels. Obviously, in the androgen- 
responsive cells androgen receptor mRNA 
can be detected. In contrast, in the androgen-in- 
dependent cells, not only the androgen receptor 
is absent, but also the corresponding mRNA. 
Regulation of androgen receptor mRNA ex- 
pression in LNCaP cells 
To study further regulation of androgen 
receptor mRNA expression in prostate cells, 
LNCaP cells were cultured in steroid-depleted 
medium and subsequently their growth was 
stimulated by the addition of fetal calf serum up 
to a concentration f 5% or the synthetic andro- 
gen R1881 (10 -~° M) (Fig. 1A and Refs [17, 30]). 
RNA was extracted from serum- and R1881- 
treated cells and androgen receptor mRNA 
expression was compared with the control cul- 
ture in steroid-depleted medium. In addition, 
regulation of androgen receptor mRNA ex- 
pression was compared with that of mRNA of 
the prostate-specific tumor marker prostate- 
specific antigen [23]. As can be seen, both R1881 
and fetal calf serum strongly increased the level 
of prostate-specific antigen mRNA (Fig. 1C). In 
contrast, androgen receptor mRNA expression 
was downregulated by R1881 treatment and 
stable or slightly upregulated by serum treat- 
ment (Fig. 1B). Because both addition of fetal 
calf serum and R1881 to the culture resulted in 
growth stimulation of LNCaP cells, these data 
point to a complex mechanism of androgen 
receptor mRNA expression i  correlation with 
cell growth. 
Structure of the androgen receptor for LNCaP 
cells 
Previously we reported the aberrant affinity 
for steroid hormones of androgen receptor 
preparations from LNCaP ceUs [31, 32]. In 
order to establish whether a mutation in the 
androgen receptor gene could be the cause of its 
abnormal properties, androgen receptor cDNA, 
and the exons 2-7 and the protein coding part 
of exon 8 of the androgen receptor gene were 
sequenced after amplification of the appropriate 
fragments by the polymerase chain reaction. In 
the androgen receptor gene as well as the cDNA 
one point mutation was detected. This mutation 
(A to G) resulted into the transition of amino- 
acid residue 868, threonine into an alanine 
(Fig. 2). It is tempting to speculate that this 
mutation is the cause of the modified specificity 
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Fig. 1. Growth regulation of the human prostate carcinoma 
cell line LNCaP (A), regulation of androgen receptor 
mRNA expression (B) and regulation of prostate-specific 
antigen mRNA expression (C) by R1881 and fetal calf 
serum. Experimental details are described inthe Experimen- 
tal section. Abbreviations: DCC or DCC-FCS: Dextran- 
charcoal-treated fetal calf serum; bAR: human androgen 
receptor; PSA: prostate-specific antigen. For sizes of mRNA 
species (in kb) see refs [7] and [23]. Hybridization of the 
Northern blots with an actin probe was used as an internal 
control. 
DISCUSSION 
The molecular mechanisms ofprostate tumor 
cell growth are not understood. A key molecule 
in normal prostate development and in andro- 
gen-dependent prostate tumor growth is the 
androgen receptor. In this study the regulation 
of expression of androgen receptor mRNA 
and the structure of the androgen receptor of 
LNCaP cells are described. 
840 J. TRAPMAN et al. 
Binding domoin 
DNA Androgen 
549 623 661 910 
860 868 876 
I A R E L H Q F T F D L L I K S H 
A 
Fig. 2. Schematical representation of the androgen receptor structure. The open box (amino-acids 
549-623) shows the DNA-binding domain; the closed box (amino-acids 661 910) the steroid-binding 
domain. The mutation i the androgen receptor fLNCaP cells (threonine toalanine) isat position 868. 
First of all, it was observed that androgen 
receptor mRNA is absent or present in only 
very low concentrations in androgen-indepen- 
dent human prostate cell lines and transplanted 
human prostate tumors, showing that down- 
regulation of androgen receptor expression in 
androgen-independent cell lines/tumors is on 
the mRNA level (Table 1). The downregulation 
of androgen receptor mRNA expression can be 
caused by an increased egradation rate of the 
mRNA, but more likely by a decrease in tran- 
scription rate of the androgen receptor gene. 
Similar findings were recently reported in the 
rat Dunning prostate tumor model[33]. In 
most, but not all, androgen-independent sub- 
lines of the Dunning prostate tumor, androgen 
receptor mRNA expression was downregulated, 
whereas it was present in the androgen- 
dependent cell lines. Interestingly, androgen re- 
ceptor mRNA could clearly be detected in 
the androgen-independent sublines, which were 
derived directly from the original androgen- 
dependent tumor. This indicates that loss of 
androgen receptor mRNA expression can be a 
functional late step in progressive tumor 
growth. Alternatively, the absence of androgen 
receptor mRNA in androgen-independent cell 
lines/tumors might simply be due to loss of 
differentiated functions of the tumor cells 
during long-term in vitro culture or transplan- 
tation, which is not a reflection of the situation 
in vivo. Recent immunohistochemical analysis of 
tissue sections of human prostatectomy speci- 
mens showed that the androgen receptor is 
present in essentially all differentiated tumor 
growth patterns, whereas androgen receptor 
expression seems more variable in undifferenti- 
ated tumor growth patterns [14]. Extension of 
these experiments and detailed investigation of 
androgen receptor expression during tumor 
growth will have to be carried out in order to 
determine whether the presence or absence of a 
(functionally active) androgen receptor plays a 
role in human prostate cancer progression. 
Analysis of regulation of androgen receptor 
mRNA expression in the androgen-sensitive 
LNCaP cell line showed that there is no strict 
correlation between cell growth and androgen 
receptor mRNA level. Stimulation of LNCaP 
growth by the synthetic androgen R1881 is 
accompanied by downregulation of androgen 
receptor mRNA levels. If full serum is used 
for growth stimulation such a downregulation 
cannot be observed. The latter indicates that 
components other than testosterone, which have 
been removed from the serum by dextran 
charcoal treatment can contribute to regulation 
of androgen receptor mRNA levels. Whether 
this is on the level of gene transcription remains 
to be established. 
The mutation detected at position 868 in 
the steroid-binding domain of the androgen 
receptor of LNCaP cells is of high interest. This 
mutation might render the androgen receptor 
more susceptible to activation by steroids other 
than testosterone and dihydrotesterone ( .g. 
progesterone, oestradiol) [31, 32]. The mutated 
receptor seems to be completely functional. Not 
only cell growth can be stimulated by R1881, 
but also prostate-specific antigen mRNA ex- 
pression can be upregulated (Fig. 1). It is tempt- 
ing to speculate that the mutation plays a role 
in progressive prostate tumor growth. In this 
respect it is of importance that the tumor from 
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which the LNCaP cell line is derived continued 
to grow during estrogen therapy [34]. 
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